Platelet count and dose, but not comorbidities, predict severe neutropenia in cabazitaxel-treated prostate cancer patients: A retrospective observational study
Int. Journal of Clinical Pharmacology and Therapeutics · 2023
DOI: 10.5414/cp204393 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2023. Verfasst von Noriaki Kataoka und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Neutropenia, Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Kataoka, N., Hata, T., Hosomi, K., Hirata, A., Goto, E., Nishihara, M., Inamoto, T., Azuma, H., & Neo, M. (2023). Platelet count and dose, but not comorbidities, predict severe neutropenia in cabazitaxel-treated prostate cancer patients: A retrospective observational study. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204393
Vancouver
Kataoka N, Hata T, Hosomi K, Hirata A, Goto E, Nishihara M, et al. Platelet count and dose, but not comorbidities, predict severe neutropenia in cabazitaxel-treated prostate cancer patients: A retrospective observational study. Int. Journal of Clinical Pharmacology and Therapeutics. 2023. doi:10.5414/cp204393
BibTeX
@article{Kataoka2023,
author = {Kataoka, Noriaki and Hata, Takeo and Hosomi, Kouichi and Hirata, Atsushi and Goto, Emi and Nishihara, Masami and Inamoto, Teruo and Azuma, Haruhito and Neo, Masashi},
title = {Platelet count and dose, but not comorbidities, predict severe neutropenia in cabazitaxel-treated prostate cancer patients: A retrospective observational study},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2023},
doi = {10.5414/cp204393}
}
EUVIMED